45 completed, 17 recruiting, 13 terminated, 8 withdrawn. 34 Not applicable, 33 Phase 2, 25 Phase 3, 6 Phase 1, 5 Phase 4.
Follow SOC: new trials by email Literature Review of SOC trials Research Report on SOC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study in Pediatric Participants Aged ≥2 to <12 Years With a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis Antibiotics Gepotidacin, SOC - Urinary Tract Infections | Phase 1 | Not yet recruiting | GlaxoSmithKline | 25 | 2026-09-18 | 2026-09-28 |
| Improving Maternal and Child Health Through Point-of-care STI Testing Point-of-care STI tests, Standard of care STI testing - Treponema Pallidum Infection, Chlamydia Trachomatis Infection | Not applicable | Recruiting | Emory University | 756 | 2026-08-11 | 2026-08-19 |
| A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors ARV-6723, Pembrolizumab, SOC - Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | Arvinas Inc. | 499 | 2026-07-29 | 2026-10-13 |
| Comparative Assessment of Inclisiran on Top of Standard of Care Versus Standard of Care Alone for LDL-C Evaluation in Acute Coronary Syndrome Patients in Saudi Arabia inclisiran, SOC - Acute Coronary Syndrome | Phase 4 | Not yet recruiting | Novartis Pharmaceuticals | 300 | 2026-06-30 | 2026-07-06 |
| Evaluation of the Efficacy of Hyalomatrix® in the Healing of Chronic Venous Leg Ulcers Hyalomatrix, Standard of Care - Venous Leg Ulcer, Chronic Wounds | Not applicable | Recruiting | NuScience Medical Biologics, LLC | 122 | 2026-05-14 | 2026-06-30 |
| Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies SERD* + abemaciclib, SERD* + everolimus, SERD* + everolimus or capecitabine - Breast Cancer, Metastatic Breast Cancer | Phase 2 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 700 | 2026-02-16 | 2026-09-18 |
| LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer Exercise Therapy, Fasting-Mimicking Diet, SOC - Triple Negative Breast Cancer (TNBC), Early Setting | Phase 2 | Recruiting | Universitaire Ziekenhuizen KU Leuven | 356 | 2026-02-01 | 2026-08-07 |
| Evaluating the Efficacy of OCM™ (Omeza® Complete Matrix) in the Treatment of Diabetic Foot Ulcers Omeza® Complete Matrix, Standard of Care - Diabetic Foot Ulcer | Not applicable | Recruiting | Omeza, LLC | 180 | 2025-12-04 | 2026-08-04 |
| UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML Idarubicin Hydrochloride, Fludarabine, Cytarabine (Ara-C) - Acute Myeloid Leukemia, Pediatric AML | Early Phase 1 | Recruiting | Baylor College of Medicine | 36 | 2025-10-22 | 2026-08-24 |
| A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy VS-01 on top of SOC (Active Treatment Group), SOC - Hepatic Encephalopathy, Acute on Chronic Liver Failure (ACLF) | Phase 2 | Terminated | Genfit | 3 | 2025-08-25 | 2026-01-12 |
| Post Stroke Ambulation Recovery Using Robotic Exoskeletons Robotic Exoskeleton, SOC - Hemiparesis After Stroke | Not applicable | Recruiting | Kessler Foundation | 96 | 2025-05-15 | 2025-09-02 |
| Reengineering Cervical Cancer Screening for the 21st Century: Joint Action for a Novel Up-to-date and Sustainable Screening Program Invitation of all participants to CCS according to the standard of care (active comparator), Invitation of all participants to CCS through self-sampling, Invitation of all participants to CCS, asking them to choose between self-sampling and the standard of care - Cervical Cancer Screening | Not applicable | Enrolling by invitation | Instituto de Saude Publica da Universidade do Porto | 5700 | 2025-04-10 | 2025-04-23 |
| P3 Trial: Estimating the Impact of a Multilevel, Multicomponent Intervention to Increase Uptake of HIV Testing and Biomedical HIV Prevention DIY (Do It Yourself), TRUST, SOC - HIV Testing, PrEP Uptake | Not applicable | Recruiting | Columbia University | 480 | 2024-12-19 | 2026-08-31 |
| Geriatric Oncology Care in Brazil: Remote Geriatric Assessment-Driven Interventions With Supportive Care GAIN-S Multidisciplinary Telehealth Intervention, Standard Oncology Care - Geriatric Assessment, Geriatric Oncology | Phase 3 | Enrolling by invitation | Cristiane Decat Bergerot, PhD | 350 | 2024-12-06 | 2025-07-24 |
| Effect of Perioperative Oral Rifaximin on Early Graft Dysfunction in Adult Living Donor Liver Transplant Rifaximin 550 MG, SOC - Chronic Liver Disease | Not applicable | Recruiting | Institute of Liver and Biliary Sciences, India | 100 | 2024-12-01 | 2025-03-05 |
| Miro3D Wound Matrix Study for Diabetic Foot Ulcers and Wound Healing Miro3D Wound Matrix, Standard of Care (SOC) - Diabetic Foot Ulcers (DFUs), Chronic Wound of the Lower Limb (Leg Ulcer or Foot Ulcer) | Not applicable | Recruiting | Reprise Biomedical, Inc. | 30 | 2024-11-01 | 2025-12-24 |
| Study Evaluating Several CAMPs in Nonhealing Diabetic Foot and Venous Leg Ulcers Amnion-Intermediate-Chorion, Amnion-Chorion-Amnion, Standard of Care - Diabetic Foot Ulcer, Venous Leg Ulcer | Phase 4 | Completed | Cellution Biologics | 292 | 2024-10-14 | 2026-04-13 |
| Extended Remdesivir Infusion Combined With Nirmatrelvir/Ritonavir for Persistent SARS-CoV-2 Infection in Immunocompromised Patients combination therapy, SOC - COVID-19, SARS-CoV-2 | Not applicable | Not yet recruiting | National Taiwan University Hospital | 40 | 2024-09-21 | 2024-09-25 |
| Evaluating the Efficacy of a Single Layer Placental-based Allograft and Standard of Care Versus Standard of Care SLAM + SOC, SOC - Diabetic Foot Ulcer, Diabetic Foot | Not applicable | Recruiting | Applied Biologics, LLC | 124 | 2024-09-20 | 2024-11-20 |
| Trial to Evaluate Nitazoxanide for Treatment of Mild or Moderate COVID-19 in Subjects at High Risk of Severe Illness Nitazoxanide, Vitamin Super-B Complex, Placebo - COVID-19 | Phase 3 | Withdrawn | Romark Laboratories L.C. | 2024-08-01 | 2024-09-24 |
Showing 20 of 100. Sign in to see all of them.
COVID-19 (16) · Diabetic Foot (5) · Coronavirus Infections (4) · Hyperthermia (4) · Triple Negative Breast Neoplasms (4) · Breast Neoplasms (3) · Foot Ulcer (3) · HIV Infections (3) · Leukemia, Myeloid, Acute (3) · Acquired Immunodeficiency Syndrome (2) · Antiphospholipid Syndrome (2) · Asthma (2) · Bronchiolitis Obliterans (2) · Carcinoma, Non-Small-Cell Lung (2) · Clostridium Infections (2)
Columbia University (4) · Medtronic Surgical Technologies (4) · GlaxoSmithKline (3) · National Taiwan University Hospital (3) · PENTA Foundation (3) · Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA (2) · Merck Sharp & Dohme LLC (2) · Novartis Pharmaceuticals (2) · Ruijin Hospital (2) · Shire (2) · Zambon SpA (2) · Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) (1) · American Regent, Inc. (1) · Angiodynamics, Inc. (1) · Applied Biologics, LLC (1)
United States (49) · Spain (15) · United Kingdom (14) · France (13) · Belgium (10) · Germany (8) · Italy (8) · South Africa (7) · China (6) · Argentina (5) · Australia (4) · Israel (4) · Netherlands (4) · Portugal (4) · Russia (4)
Abhay Gupta, MD (2) · Angelina Ferguson, DNP (2) · Paola Castellani, MD (2) · Adrian Hepner (1) · Alison Murray (1) · Anastasia Pokrovskaya, PhD (1) · Anders G Vahlne, Professor (1) · Andrea A Howard, MD (1) · Andrew Meltzer, MD (1) · Ann Smeets, MD, PhD (1) · Antonio Ramos, MD, PhD (1) · Carl-Johan Wickerts, MD (1)
PMID 28121498, PMID 29538686, PMID 29788418, PMID 30060024, PMID 30227108, PMID 30455246, PMID 30460321, PMID 31411386, PMID 31628838, PMID 32099847, PMID 32376702, PMID 32504314, PMID 36661328, PMID 38873891, PMID 41858082, PMID 23398660, PMID 27316794, PMID 27629486, PMID 28395936, PMID 29157275, PMID 29502195, PMID 29949045, PMID 30064405, PMID 31047111, PMID 31251094, PMID 31507641, PMID 31846705, PMID 31883370, PMID 32101275, PMID 32641032, PMID 32763217, PMID 33225960, PMID 33446115, PMID 33472681, PMID 33789009, PMID 33848093, PMID 34013969, PMID 34098955, PMID 34158028, PMID 34231041, PMID 34233640, PMID 34473652, PMID 34545530, PMID 34747368, PMID 34817414, PMID 34965338, PMID 35413921, PMID 35868341, PMID 36041750, PMID 36055295
2016 (3), 2018 (3), 2014 (2), 2025 (2), 2017 (1), 2019 (1), K01AI104351 (1), P01AA029540 (1), R01HD074558 (1), R01MD020754 (1), R01MH129198 (1), R01MH131415 (1), R21CA191594 (1)